公司资料
Mesoblast 股价、新闻与催化剂
- 股票代码:
- MESO
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- Australia and listed in the U
股票表现
14.87 USD (+3.19%)
收盘价
最后更新: 2026年9月17日
1.88B USD
市值
股价为何变动
截至 2026年9月17日，MESO 上涨 3.19%，收于 $14.87。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
Mesoblast is a regenerative medicine company focused on cell-based therapies for inflammatory and degenerative diseases. Its platform has long centered on developing allogeneic cell therapies with broad medical use.
所在地与行业分类
Headquartered in Australia and listed in the U.S. as an ADR, Mesoblast sits in cell therapy and regenerative medicine.
商业模式特征
The company depends on clinical validation, manufacturing execution, and the ability to commercialize cell-based medicine.
生物医药行业定位
Mesoblast is a long-running regenerative-medicine name whose valuation depends on clinical and commercial milestones.
未来催化剂
- Mesoblast's catalysts are Ryoncil commercialization and any broader cell-therapy expansion. The stock will care about whether the commercial base keeps building.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。